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Summary IL-2, in addition to its immunomodulating and antitumour properties, induces important systemic
actions, including cardiovascular, neuroendocrine and metabolic effects. The present study was carried out to
evaluate IL-2 effects on cholesterol metabolism. The study included 14 advanced cancer patients (renal
carcinoma: ten; colon carcinoma: four), who received IL-2 subcutaneously at a dose of 1.8 x 106 IU ml-2 twice
daily for 5 days/week for 6 weeks. Venous blood samples were collected 7 days before, on days 0, 3, 7, 14, 21,
42 of IL-2 therapy, and on days 14 and 28 of the rest-period. IL-2 induced a rapid and evident decrease in
cholesterol levels, with a normalisation of its concentrations within 7 days in 10/10 hypercholesterolemic
patients. The lowest mean levels ofcholesterol were reached within the first 2 weeks; after that they still slowly
increased. LDL-/HDL-cholesterol ratio was significantly reduced by IL-2 therapy. Cholesterol fall was
associated with a marked increase in conjugated biliary acid levels. Finally, triglyceride values increased during
IL-2 therapy, but not in a significant manner. These results, by showing that IL-2 exerts an evident and very
rapid cholesterol-lowering activity, would represent a further demonstration of the physiological importance of
cytokines in the control of cholesterol metabolism.
The administration of interleukin-2 (IL-2) in the immuno-
therapy of cancer may induce important cardiovascular com-
plications, including a severe hypotension, an increased
capillary permeability, and cardiac ischaemic disorders
(Rosenberg et al., 1987; Lee et al., 1989). These side-effects
are less evident when IL-2 is subcutaneously given (Atzpo-
dien et al., 1990). Hepatic, renal and haematological toxicities
have been also observed during IL-2 immunotherapy (Rosen-
berg et al., 1987). Moreover IL-2, as well as other cytokines,
in addition to its immunomodulating properties, may also
induce important endocrine and metabolic effects (Denicoff et
al., 1989; Chambrier et al., 1990). Among the metabolic
effects ofcytokines, granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF) has been shown to reduce cholesterol
levels (Nimer et al., 1988). Moreover, tumour necrosis factor
(TNF) has appeared to cause hypertriglyceridemia (Sherman
et al., 1988). On the contrary, only few data are available up
to now about the possible influence of IL-2 on lipid meta-
bolism. Preliminary results have shown a reversible and acute
hypocholesterolemia during cancer immunotherapy with high-
dose intravenous IL-2 (Wilson et al., 1989). However, the
important toxicity of high-dose intravenous IL-2 excludes the
possible investigation of IL-2 efficacy in the treatment of
cholesterol metabolism disorders. The present study was per-
formed to evaluat' the effect of low-dose subcutaneous IL-2
on cholesterol levels and on its fractions in patients with
advanced solid neoplasms.
Materials and methods
Between March 1990 and January 1991, a total of 14 con-
secutive advanced cancer patients (M/F: 11/3; median age 56
years, range 24-72), followed at San Gerardo Hospital of
Monza, entered the study to be treated with IL-2. Ten
patients were affected by renal adenocarcinoma, and the
remaining four cases by colon adenocarcinoma. Human
recombinant IL-2 was supplied by Euro-Cetus (Amsterdam-
Holland). IL-2 was subcutaneously injected into different
parts of the abdominal wall. The treatment protocol con-
sisted of a 2-day IL-2 pulse of 9 x 106 IU m-2 twice daily,
followed by 6 weeks of IL-2 at 1.8 x 106 IU m-2 every 12 h
for 5 days/week, corresponding to one IL-2 subcutaneous
cycle. Cycles were repeated after a rest period of 4 weeks.
Serum cholesterol, HDL-cholesterol, LDL-cholesterol and
triglyceride levels were measured in each patient on venous
blood samples collected at 8.00 am, after an overnight fast.
Samples were collected 7 days before the start of the
immunotherapy, on the same day of the first IL-2 injection,
on days 3, 7, 14, 21 and 42 of IL-2 cycle, and on days 14 and
28 of rest period. Moreover, in six patients we have also
measured serum levels of conjugated biliary acids by collect-
ing blood samples before IL-2, and on days 3 and 7 of the
cycle. Patients followed a dietary regimen consisting of
35 KCal/kg/ideal body weight/day. No patient received drugs
influencing cholesterol metabolism during the study. Routi-
nary laboratory tests were repeated every week.
Cholesterol and triglyceride serum levels were measured
with a colorimetric method, by using commercial kits (Poli-
Industria Chimica, Milan-Italy). HDL- and LDL-cholesterol
levels were also determined with a colorimetric method, after
lipoprotein precipitation with phosphotungstic acid and
magnesium chloride by using commercial kits (Behring, Ger-
many). Finally, serum levels of conjugated biliary acids were
measured by RIA, by using commercially available kits
(Becton-Dickinson, Orangeburg, NY). The normal values
obtained in our laboratory in 100 age- and sex-matched
healthy subjects (median age 55 years; range 30-60) and
expressed as 95% confidence limits were the following ones:
cholesterol: 110-200 mgdl-'; HDL: 35-80 mg dl-'; LDL:
60-160mg dl-'; triglycerides: 70-160mgdl-'; conjugated
biliary acids: 0.6-6 imoll- .
Data are shown as mean ± s.e. Results were analysed by
the Student's t-test, and analysis of variance according to
Newman Keuls test and adjusted for a correction factor.
Results
No ischaemic cardiac toxicity was seen during IL-2 subcu-
taneous therapy. No important emesis or anorexia occurred
during the treatment, and no change in dietary regimen was
observed. No patient had changes in body weight greater
than 2% during IL-2 cycle. Finally, no important anaemia
requiring blood transfusions was seen during the study. An
increase greater than 100% in gamma-GT and a mild rise of
transaminases were seen in all patients, whereas no signi-
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ficant change in total bilirubin mean concentrations was
observed during the immunotherapy with IL-2.
Individual values of cholesterol, HDL-, and LDL-choles-
terol, found during IL-2 cycle, are reported in Table I, while
their mean concentrations are illustrated in Figure 1. Abnor-
mally high levels of cholesterol were seen in 10/14 patients
before the start of IL-2 immunotherapy. Cholesterol concen-
trations fell rapidly with the start of IL-2 administration,
with a normalisation of its values in 10/10 hypercholesterol-
emic patients within 7 days from the beginning of IL-2
therapy. The maximum inhibitory effect on cholesterol levels
was obtained within the first 2 weeks of IL-2 therapy; after
that, no further decrease was obtained. Mean concentrations
of cholesterol significantly decreased during IL-2 treatment,
with the lowest levels on day 7 (P<0.001 vs before). Despite
IL-2 administration, cholesterol levels slowly increased after
the second week of therapy, and their mean levels found on
day 42 were not significantly different from those seen before.
Cholesterol rapidly increased in all patients at IL-2 interrup-
tion, and its concentrations became substantially similar to
those seen before within the 28th day of rest period. Both
HDL- and LDL-cholesterol significantly decreased during IL-
2 therapy, with a pattern similar to the one showed by the
total cholesterol. LDL-/HDL-cholesterol mean ratio, observ-
ed during IL-2 therapy, was lower than that seen before, with
a difference statistically significant (2.9 ± 0.2 vs 3.8 ± 0.3;
P = 0.01). Triglycerides means concentrations progressively
increased during IL-2 administration, without, however, any
significant difference in respect to those seen before. The
peak in triglycerides levels was delayed in respect to the fall
in cholesterol values (see Figure 1). Finally the mean levels of
conjugated biliary acids significantly increased in response to
IL-2 injection, with a peak on day 3 (before: 4.2 ± 0.9 limol
1-l; after: 15.2 ± 2.5ltmol l-l; P<0.005).
Discussion
The results of this study show that the subcutaneous admini-
stration of low-dose IL-2 is able to normalise cholesterol
levels in hypercholesterolemic cancer patients. Therefore, this
study confirms also with low-dose IL-2 subcutaneous therapy
the results previously described by other authors (Wilson et
al., 1989) with very high doses of IL-2 given intravenously.
The IL-2 cholesterol-lowering activity seems to be more rapid
and pronounced than that of 3-hydroxyl-3-methylglutaril-
coenzyme A (HMG-CoA) reductase inhibitors (Tobert, 1987),
and comparable to that observed with GM-CSF (Nimer et
al., 1988). HDL- and LDL-cholesterol are both involved in
IL-2-induced fall in total cholesterol concentrations, even
though LDL-/HDL-cholesterol ratio decreases during IL-2
subcutaneous therapy, with a following improvement in
terms ofprotection against coronary heart disease (Gorden et
al., 1979). Moreover, this study shows that the decrease in
juu-
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Figure 1 Serum levels (mean±s.e.) of cholesterol, HDL-, LDL-
cholesterol and triglycerides before and during IL-2 subcutaneous
therapy in 14 advanced cancer patients.
cholesterol levels during IL-2 therapy is associated with an
increase in triglyceride concentrations. The IL-2-induced
TNF rise (Nedwin et al., 1985) would explain triglyceride
increase, but not the fall in cholesterol, which does not seem
to be influenced by TNF (Sherman et al., 1988). Moreover,
at present it is unknown whether IL-2 per se may be respon-
sible for cholesterol-lowering activity, or whether this effect
may depend on other cytokines produced in response to
IL-2, particularly GM-CSF itself, which secretion is
stimulated by IL-2 (Michalevicz et al., 1988). The evidence of
a concomitant decrease in HLD- and LDL-cholesterol would
suggest an inhibition ofcholesterol synthesis, whereas we can
exclude that cholesterol fall may be simply due to changes in
body weight or in the dietary regimen, since no patient
showed important nausea, anorexia or body weight varia-
tions during IL-2 therapy. The decline in cholesterol syn-
thesis could be due to a direct inhibition of HMG-CoA
reductase, or to a stimulation of LDL and scavenger mac-
rophage receptors, which play a main role in the removal of
cholesterol and in the formation of foam cells (Goldstein et
al., 1979). In fact, activated T lymphocyte products, which
contain IL-2, have been shown either to inhibit HMG-CoA
reductase activity (Fogelman et al., 1982), or to modulate
LDL macrophage receptor expression (Fogelman et al.,
1983). Therefore, we cannot exclude a direct action of IL-2
on hepatic macrophages, which express IL-2 receptors (Mal-
kovsky & Sondel, 1987) and release factors acting on
cholesterol metabolism (Cai et al., 1988). However, the IL-2-
induced hepatic function damage, as documented by the
increase in transaminases and in gamma-GT, could also play
a role in determining a reduced cholesterol synthesis, whereas
Table I Clinical data and individual serum levels (mg dl) ofcholesterol (C), HDL-cholesterol (H), LDL-cholesterol
(L) and LDL-/HDL-cholesterol ratio (R) before and during IL-2 subcutaneous therapy in 14 advanced cancer
patients
Prior to study Mininum on study Cholesterol
Patient Sex Age Tumour histotype C H L R C H L R reduction %
I M 59 Renal cancer 240 22 118 5.4 163 13 48 3.7 32
2 M 24 Renal cancer 181 47 122 2.6 159 18 37 2.1 17
3 M 67 Renal cancer 241 40 151 3.8 151 21 61 2.9 37
4 M 59 Renal cancer 248 33 159 4.8 89 16 66 3.9 64
5 F 68 Renal cancer 258 39 185 4.7 110 20 49 2.5 57
6 M 49 Renal cancer 153 44 104 2.4 91 24 41 1.7 62
7 M 58 Renal cancer 233 31 157 5.1 154 18 71 3.9 34
8 F 52 Renal cancer 158 43 101 2.3 86 23 57 2.5 46
9 F 55 Renal cancer 265 39 176 4.5 110 21 47 2.2 59
10 M 60 Renal cancer 154 42 103 2.4 107 22 56 2.4 31
11 M 55 Colon cancer 238 41 175 4.2 127 19 71 3.7 47
12 M 72 Colon cancer 215 35 159 4.5 140 26 72 3.4 35
13 M 57 Colon cancer 202 34 107 3.1 109 19 41 2.2 46
14 M 49 Colon cancer 209 39 145 3.7 85 16 58 3.6 59
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other factors, including leukocyte proliferation (Rosenberg et
al., 1987) and cortisol rise (Denicoff et al., 1989) induced by
IL-2, would not be enough to explain the rapid and very
pronounced fall in cholesterol levels, which occurs within few
days from the start of IL-2 therapy, and precedes leukocyte
proliferation.
The progressive decline with time in IL-2 cholesterol-
lowering activity, observed in this study despite the con-
tinuous IL-2 injection and not shown by Wilson et al. (1989)
with a shorter period of administration, might depend on a
possible down-regulation of IL-2 macrophage receptors,
determined by the prolonged administration of IL-2. The
difference between our results and those referred by Wilson
et al. (1989), who described a more rapid return to baseline
values with IL-2 interruption, could be due to differences in
doses, route and schedule of IL-2 therapy.
The evidence that IL-2 affects cholesterol metabolism
would suggest a possible role of IL-2, which endogenous
availability decreases with age (Saadeh et al., 1986), in the
pathogenesis of atherosclerosis, as recently proposed for
other cytokines (Ross, 1986). If future studies will confirm
also in non-oncologic hypercholesterolemic patients its
cholesterol-lowering activity, clinical trials will be justified to
investigate the possible use of IL-2 in the treatment ofcholes-
terol metabolism disorders.
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